Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Disorders Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Feasibility of ActivSightTM in Human

NCT04633512
View directory record Official record
Conditions
Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions
ActivSight
Device
Lead sponsor
Activ Surgical
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 25, 2026, 6:45 AM EDT
Terminated No phase listed Observational

Bilateral and Unilateral Amblyopia Treatment Study

NCT03780205
View directory record Official record
Conditions
Amblyopia
Interventions
Prescription glasses for bilateral amblyopia, Prescription glasses for unilateral amblyopia
Other
Lead sponsor
Salus University
Other
Eligibility
3 Years to 10 Years
Enrollment
1 participant
Timeline
2019 – 2020
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 25, 2026, 6:45 AM EDT
Enrolling by invitation No phase listed Observational

Binocular and Monocular Distance-Corrected Visual Performance and Defocus Characteristics of Clareon Truplus Intraocular Lens (IOL)

NCT07589894
View directory record Official record
Conditions
Cataract, Cataract Surgery, Cataract Bilateral, Cataract (Post-operative Cataract Surgery Follow-up)
Interventions
Clareon TruPlus IOL
Device
Lead sponsor
Colvard Kandavel Eye Center
Other
Eligibility
50 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

Factors in Learning And Plasticity: Macular Degeneration

NCT05454124
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Training visual sensitivity, Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

NCT03178786
View directory record Official record
Conditions
Parkinson Disease
Interventions
PAT sessions
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 25, 2026, 6:45 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans

NCT07508722
View directory record Official record
Conditions
Healthy Volunteers, no Condition, Basic Science
Interventions
Transcranial Focused Ultrasound Stimulation, Electroencephalography, Magnetic Resonance Imaging
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MS-ResearchBiomarkerS

NCT05204459
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

NCT01173874
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Remediation
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Granada Hills, California • Orange, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 25, 2026, 6:45 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects

NCT04984590
View directory record Official record
Conditions
Low Vision, Age Related Macular Degeneration
Interventions
IOPCL AMD MAG
Device
Lead sponsor
OnPoint Vision Inc
Industry
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 25, 2026, 6:45 AM EDT
Terminated Not applicable Interventional Results available

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

NCT02175745
View directory record Official record
Conditions
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Recurrent Adult Brain Tumor, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilomyxoid Astrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligoastrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Cerebellar Astrocytoma, Untreated Childhood Cerebral Astrocytoma, Untreated Childhood Diffuse Astrocytoma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Gemistocytic Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligoastrocytoma, Untreated Childhood Oligodendroglioma, Untreated Childhood Pilomyxoid Astrocytoma, Untreated Childhood Protoplasmic Astrocytoma, Untreated Childhood Subependymal Giant Cell Astrocytoma, Untreated Childhood Visual Pathway and Hypothalamic Glioma, Untreated Childhood Visual Pathway Glioma
Interventions
18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT), Magnetic resonance imaging
Drug · Procedure
Lead sponsor
Erik Mittra
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 25, 2026, 6:45 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 25, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Kubota Glass Parameter Refinement Study

NCT06085430
View directory record Official record
Conditions
Myopia, Myopia, Progressive, Vision Disorders
Interventions
Kubota Glass
Device
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
8 Years to 24 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 25, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

NCT06293300
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
BoNT A
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

NCT00352495
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Interventions
carboplatin, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 25, 2026, 6:45 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurolens Headache Study

NCT05070767
View directory record Official record
Conditions
Binocular Vision Disorder, Convergence Insufficiency, Headache, Computer Vision Syndrome
Interventions
Neurolens spectacle lens, Placebo spectacle lens
Device
Lead sponsor
Neurolens Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Conyers, Georgia • Perry, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle

NCT01234207
View directory record Official record
Conditions
Presbyopia
Interventions
Standard, non-free-form, non-customized PAL spectacles, Individually customized free-form surfaced PAL spectacles
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
39 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Phase 2Phase 3 Interventional

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

NCT01203436
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Blindness
Interventions
Supplemental Oxygen Management, Conventional Oxygen Management
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
9
States / cities
Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 25, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy for People With Physical Disabilities

NCT05695430
View directory record Official record
Conditions
Suicide, Suicide, Attempted, Suicidal Ideation, Disability Physical, Disability Hearing, Disability, Vision
Interventions
Brief Cognitive Behavioral Therapy for People with Physical Disabilities
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311
View directory record Official record
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 6:45 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study

NCT01728883
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Home vision monitoring using myVisionTrack®
Device
Lead sponsor
Vital Art and Science Incorporated
Industry
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 25, 2026, 6:45 AM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 25, 2026, 6:45 AM EDT
Not yet recruiting Not applicable Interventional

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD)

NCT06989424
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Colonoscopy
Interventions
Magnetic Flexible Endoscope (MFE)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 6:45 AM EDT